Atossa Therapeutics (ATOS) Earnings Analysis

Atossa Therapeutics (ATOS) next reports earnings on 2026-08-11, consensus EPS -1.04 USD. Last quarter (2026-05-08) it beat with EPS -1.11 USD vs -1.22 USD est (+9%). It has beaten estimates in 3/4 recent quarters (75%). Trailing P/E -0.56.

Last updated 2026-07-23 · Source: FMP fundamentals + earnings calendar (company filings); consensus from sell-side analyst grades

When does ATOS next report earnings?

Next earnings date2026-08-11
Consensus EPS estimate-1.04 USD
Revenue estimaten/a

ATOS earnings history — beats and misses

Quarter (report date)EPS actualEPS est.SurpriseResult
2026-05-08-1.11 USD-1.22 USD+9%Beat
2026-03-25-1.19 USD-1.1375 USD-4.6%Miss
2025-11-12-1.05 USD-1.05 USD0%Beat
2024-08-12-0.05 USD-0.05 USD0%Beat

Beat rate: 3/4 (75%) over reported quarters with consensus data.

ATOS valuation and analyst view

Trailing P/E-0.56
Trailing EPS-4.36555 USD
Price / book0.69
Dividend yield0.00%
Market cap0.02B
Analyst consensusBuy (4 buy / 1 hold / 0 sell)
Avg price target10 USD

Related research pages

Frequently asked questions

When is Atossa Therapeutics (ATOS)'s next earnings date?

Atossa Therapeutics is next scheduled to report on 2026-08-11, with a consensus EPS estimate of -1.04 USD.

Did ATOS beat earnings last quarter?

In its 2026-05-08 report, ATOS posted EPS of -1.11 USD versus a -1.22 USD estimate — a beat of 9%.

What is ATOS's earnings track record?

Over the last 4 reported quarters with consensus data, ATOS beat estimates 3 times (75%).

What is ATOS's current P/E ratio and EPS?

ATOS trades at a trailing P/E of -0.56 on trailing EPS of -4.3655460864278615 USD.

What do analysts rate ATOS?

Analyst consensus is "Buy" across 5 ratings (0 strong buy, 4 buy, 1 hold, 0 sell, 0 strong sell). Average 12-month price target: 10 USD.